Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6225284 | RECORDATI RARE | Somatostatin peptides |
Jun, 2016
(7 years ago) | |
| US8299209 | RECORDATI RARE | Pharmaceutical composition comprising cyclic somatostatin analogues |
Dec, 2025
(1 year, 8 months from now) | |
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(2 years from now) | |
Signifor is owned by Recordati Rare.
Signifor contains Pasireotide Diaspartate.
Signifor has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Signifor are:
- US6225284
Signifor was authorised for market use on 14 December, 2012.
Signifor is available in solution;subcutaneous dosage forms.
Drug patent challenges can be filed against Signifor from 14 December, 2016.
The generics of Signifor are possible to be released after 14 December, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-34) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 14 December, 2012
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
SIGNIFOR family patents
